138 related articles for article (PubMed ID: 31042587)
1. IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells.
Rodrigues Alves APN; Fernandes JC; Fenerich BA; Coelho-Silva JL; Scheucher PS; Simões BP; Rego EM; Ridley AJ; Machado-Neto JA; Traina F
Cancer Lett; 2019 Aug; 456():59-68. PubMed ID: 31042587
[TBL] [Abstract][Full Text] [Related]
2. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia.
Scopim-Ribeiro R; Machado-Neto JA; Eide CA; Coelho-Silva JL; Fenerich BA; Fernandes JC; Scheucher PS; Savage Stevens SL; de Melo Campos P; Olalla Saad ST; de Carvalho Palma L; de Figueiredo-Pontes LL; Simões BP; Rego EM; Tognon CE; Druker BJ; Traina F
Invest New Drugs; 2021 Jun; 39(3):736-746. PubMed ID: 33403501
[TBL] [Abstract][Full Text] [Related]
3. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2
Fenerich BA; Fernandes JC; Rodrigues Alves APN; Coelho-Silva JL; Scopim-Ribeiro R; Scheucher PS; Eide CA; Tognon CE; Druker BJ; Rego EM; Machado-Neto JA; Traina F
Signal Transduct Target Ther; 2020 Jan; 5(1):5. PubMed ID: 32296029
[TBL] [Abstract][Full Text] [Related]
4. NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells.
de Miranda LBL; Lima K; Coelho-Silva JL; Traina F; Kobayashi SS; Machado-Neto JA
Sci Rep; 2022 Oct; 12(1):17092. PubMed ID: 36224313
[TBL] [Abstract][Full Text] [Related]
5. Repressing IRS1/2 by NT157 inhibits the malignant behaviors of ovarian cancer through inactivating PI3K/AKT/mTOR pathway and inducing autophagy.
Li CX; Men CD; Yang WH; Chen R; Zhu JH; Cheng ZP
Kaohsiung J Med Sci; 2023 Apr; 39(4):377-389. PubMed ID: 36727938
[TBL] [Abstract][Full Text] [Related]
6. Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells.
Yang Y; Chan JY; Temiz NA; Yee D
Horm Cancer; 2018 Dec; 9(6):371-382. PubMed ID: 30229539
[TBL] [Abstract][Full Text] [Related]
7. IRS1/β-Catenin Axis Is Activated and Induces MYC Expression in Acute Lymphoblastic Leukemia Cells.
Fernandes JC; Rodrigues Alves APN; Machado-Neto JA; Scopim-Ribeiro R; Fenerich BA; da Silva FB; Simões BP; Rego EM; Traina F
J Cell Biochem; 2017 Jul; 118(7):1774-1781. PubMed ID: 27987331
[TBL] [Abstract][Full Text] [Related]
8. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R
Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219
[TBL] [Abstract][Full Text] [Related]
9. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
10. The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancer.
Ibuki N; Ghaffari M; Reuveni H; Pandey M; Fazli L; Azuma H; Gleave ME; Levitzki A; Cox ME
Mol Cancer Ther; 2014 Dec; 13(12):2827-39. PubMed ID: 25267499
[TBL] [Abstract][Full Text] [Related]
11. FGFR1 overexpression renders breast cancer cells resistant to metformin through activation of IRS1/ERK signaling.
Shi Y; Ma Z; Cheng Q; Wu Y; Parris AB; Kong L; Yang X
Biochim Biophys Acta Mol Cell Res; 2021 Jan; 1868(1):118877. PubMed ID: 33007330
[TBL] [Abstract][Full Text] [Related]
12. FoxP3-miR-150-5p/3p suppresses ovarian tumorigenesis via an IGF1R/IRS1 pathway feedback loop.
Zhang Q; Zhou X; Wan M; Zeng X; Luo J; Xu Y; Ji L; Zhang JA; Fan P; Zhong J; Wu J
Cell Death Dis; 2021 Mar; 12(3):275. PubMed ID: 33723215
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
[TBL] [Abstract][Full Text] [Related]
14. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.
Flanigan SA; Pitts TM; Newton TP; Kulikowski GN; Tan AC; McManus MC; Spreafico A; Kachaeva MI; Selby HM; Tentler JJ; Eckhardt SG; Leong S
Clin Cancer Res; 2013 Nov; 19(22):6219-29. PubMed ID: 24045180
[TBL] [Abstract][Full Text] [Related]
15. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
[TBL] [Abstract][Full Text] [Related]
16. Marsdenia tenacissimae extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement.
Wang Y; Chen B; Wang Z; Zhang W; Hao K; Chen Y; Li K; Wang T; Xie Y; Huang Z; Tong X
Oncotarget; 2016 Dec; 7(50):82851-82863. PubMed ID: 27756877
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.
Simioni C; Ultimo S; Martelli AM; Zauli G; Milani D; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2016 Nov; 7(48):79842-79853. PubMed ID: 27821800
[TBL] [Abstract][Full Text] [Related]
18. Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling.
Flashner-Abramson E; Klein S; Mullin G; Shoshan E; Song R; Shir A; Langut Y; Bar-Eli M; Reuveni H; Levitzki A
Oncogene; 2016 May; 35(20):2675-80. PubMed ID: 26119932
[TBL] [Abstract][Full Text] [Related]
19. miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2.
Yang M; Shan X; Zhou X; Qiu T; Zhu W; Ding Y; Shu Y; Liu P
Anticancer Agents Med Chem; 2014; 14(6):884-91. PubMed ID: 24875127
[TBL] [Abstract][Full Text] [Related]
20. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.
Schult C; Dahlhaus M; Glass A; Fischer K; Lange S; Freund M; Junghanss C
Anticancer Res; 2012 Feb; 32(2):463-74. PubMed ID: 22287733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]